Affiliation:
1. Department of Pharmaceutics, School of Pharmacy and Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India
2. Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management SVKMs NMIMS Deemed-to-be University, V L Mehta Road, Vile Parle (West), Mumbai, 400 056, Maharashtra, India
Abstract
Abstract:
Theranostics, a method that combines targeted therapy and diagnostic imaging,
has emerged as a viable route for enhancing cancer treatment, and hybrid nanoparticles
(HNPs) are at the forefront of this field. Metallic, polymeric, lipid-based, and silica-
based HNPs are studied for targeting and biocompatibility. Using HNPs, chemotherapeutic
drugs, small interfering RNA, and therapeutic genes can be given precisely and
controlled. This enhances therapeutic efficacy and reduces adverse effects. With fluorescence
dyes, MRI contrast agents, and PET tracers, real-time therapy response monitoring
is conceivable. A nano platform with therapeutic and diagnostic capabilities holds
great promise for personalized medicine and precision oncology. The present study discusses
HNPs' biocompatibility, stability, immunogenicity, and long-term biosafety,
which are crucial to the clinical translation of cancer theranostics. Further, in this in-
-depth investigation, we investigated the design, synthesis, and multifunctional activities
of HNPs for use in cancer theranostics.
Publisher
Bentham Science Publishers Ltd.